Latest News & Features
Big Pharma
The German Court of Appeal has ruled that Indianapolis-based Eli Lilly’s European “vitamin regimen” patent for lung cancer injection Alimta would not be infringed by Actavis’s generic version. 9 March 2015
Americas
The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US. 9 March 2015
Americas
Law firm Fried, Frank, Harris, Shriver & Jacobson has added a life sciences specialist to its intellectual property litigation practice. 5 March 2015
Americas
The US Patent and Trademark Office’s Patent Trial and Appeal Board has handed down what are thought to be the first written decisions in inter partes review proceedings that concern the biopharmaceutical industry. 5 March 2015
Americas
The US Court of Appeals for the Federal Circuit has overturned a $100 million damages sum awarded to Medtronic Sofamor Danek in a long-fought patent case between the medical device maker and San Diego-based NuVasive. 4 March 2015
Americas
Life sciences lawyer Lana Gladstein has joined US law firm Nutter McClennen & Fish’s intellectual property practice as partner. 4 March 2015
Americas
AstraZeneca has closed a deal that will see it acquire the rights to Actavis’s branded respiratory drugs business in the US and Canada, it was announced today. 3 March 2015
Big Pharma
The English High Court has ordered the country’s National Health Service to issue guidance to medical professionals so that they prescribe Pfizer’s branded product Lyrica—not the generic version—for neuropathic pain. 3 March 2015
Asia
India-based generic drug maker Natco Pharma has signed a non-exclusive licensing agreement with Gilead Sciences that allows Natco to make and sell generic versions of hepatitis C drugs including Sovaldi, it was announced yesterday. 3 March 2015
Americas
Professional services firm CohnReznick has expanded its technology and life sciences industry practice group to Austin, Texas. 26 February 2015